Budgets up to $100,000 per year, and time periods up to two years for Phase I programs, may be requested, the NIH noted. Budgets up to $500,000 per year, and up to three years, may be requested for Phase II programs.
According to the NIH, "the need to combine high specificity with high potency is important to the continued development of siRNA in research and therapy development." As such, the award program "will focus on techniques and technologies leading to improved chemical synthesis and delivery of RNAi, particularly those incorporating chemical modifications that change the properties of the siRNA molecules to increase their stability and their ability to be delivered more efficiently to target cells without increasing their toxicity."
The awards will be made under the Small Business Innovation Research and Small Business Technology Transfer mechanisms, the NIH said. The number of awards will depend on the merits of the applications and the availability of funds.
Additional details about the funding opportunities are available here.